In a study of prevention of spontaneous diabetes in BB rats by therapeutic doses of cyclosporine (10 mg/kg/ day), the male control non-diabetes-prone rats showed glucose intolerance after a 0.25 g/kg glucose load by gavage, at 90 and 130 days of treatment. Non-BB male Wistar rats treated similarly showed glucose intolerance at 1 wk of treatment, with progressive worsening for 5 wk, then sustained up to 12 wk of treatment. Fasting euglycemia was maintained, but both pre-and postchallenge plasma insulin levels were significantly lower with cyclosporine at several time points. Total pancreatic insulin was decreased to one-third that of control after 5 wk. After withdrawal of cyclosporine, glucose tolerance returned to normal in 2 wk. SpragueDawley rats responded similarly and in both strains, an increase in the cyclosporine dose to 15 mg/kg/day augmented the glucose intolerance. These results demonstrate that therapeutic doses of this agent induce reversible glucose intolerance due, in part, to inhibition of insulin secretion and also possibly inhibition of synthesis, though a peripheral effect is not excluded. This hyperglycemic effect of cyclosporine has implications for its potential use in type I diabetes mellitus, transplantation, and other autoimmune disease, DIABETES 1985; 34:1309-13.
nephrotoxicity 12 and hepatotoxicity. 1 Other side effects, usually mild, include tremor (15%), hirsutism (12%), and gingival hyperplasia (6%). 3 This article documents another "side effect" of cyclosporine: induction of glucose intolerance.
The spontaneously diabetic BB rat is a widely studied animal model of type I insulin-dependent diabetes mellitus (reviewed in ref. 4) . The rat syndrome (as also the human) appears to have an autoimmune basis (reviewed in ref. 5 ). Cyclosporine has been reported to prevent diabetes occurrence in the BB rat when given before the usual age of onset, 6 " 9 but is unable to reverse either the hyperglycemia or the beta cell destruction when given at onset. 10 When cyclosporine therapy was initiated shortly after diagnosis in humans, either a 5=50% reduction in insulin dose or cessation of insulin was reported in a substantial proportion. 1112 In a previous study where we examined the immunologic changes induced by cyclosporine in relation to diabetes prevention in diabetes-prone BB rats, 13 non-diabetes-prone BB rats were used as controls. After 90 days of cyclosporine treatment, an oral glucose tolerance test was performed that unexpectedly showed glucose intolerance in the male nondiabetes-prone BB rats treated with cyclosporine. This article presents those results, as well as showing the reproducibijity of the finding that diabetes does not occur in Wistar rats unrelated to the BB colony, nor in a totally unrelated strain, Sprague-Dawley rats.
MATERIALS AND METHODS
Fourteen non-diabetes-prone male and female BB rats (Animal Resources Division, Health and Welfare Canada, Ottawa, Ontario, Canada) were treated with cyclosporine (10 mg/kg/day; Sandoz Canada Inc., Dorval, Quebec, Canada) by gavage from age 30 to 160 days. Glucose tolerance tests were performed at 120 and 160 days of age. Forty-five male Wistar rats, unrelated to the BB rats, were studied, 21 of which were treated with the same dose of cyclosporine from age 60 days, and 19 others acting as controls. Half of these rats had an oral glucose tolerance test performed after 4 h, 2 days, and 1, 2, and 5 wk of cyclosporine, and were then prepared for study of pancreatic morphology (by light mi- l-porcine-insulin and rat insulin standards (24.5 U/mg; Novo Research Laboratory, Copenhagen, Denmark), and with dextran-coated charcoal separation of bound from free insulin. Concentrations «s1000 ng/ml of cyclosporine had no effect on the insulin assay. Cyclosporine levels were measured using radioimmunoassay kits (Sandoz Canada Inc.) on plasma separated from blood without prior incubation.
RESULTS
The cyclosporine treatment was well tolerated by all rats, and their body weights were not different from those of the control rats that received the same volumes of olive oil vehicle (Tables 1 and 2). After 2 wk of cyclosporine in Wistar rats, their plasma concentrations were: 1018 ± 82 ng/ml, 4 h postdose; 1004 ± 67 ng/ml, at 8 h; 879 ± 86 ng/ml, at 16 h; and 373 ± 42 ng/ml, at the 24-h trough values. In BB rats, at 90 and 130 days of treatment (ages 120 and 160 days), all treated males showed hyperglycemia at 60 min, compared with controls (Table 1) . Female non-diabetes-prone BB rats did not show glucose intolerance, but their plasma cyclosporine levels were lower (Table 1) .
In the Wistar rats, glucose intolerance occurred after 1 wk of treatment, followed by a progressive increase of the 60 min plasma glucose during the first 5 wk of treatment ( Figure  1 ). Plasma insulin was significantly lower at time 0 and 60 min at both 7 and 12 wk of therapy. Although there was a significant increase after glucose challenge, it was less than that in controls. The fasting plasma glucose was not systematically affected (Table 2) . However, 24-h urine collections done after 12 wk of cyclosporine treatment showed glycosuria (data not shown). After 5 wk of the drug, the total pancreatic insulin was significantly lower in the cyclosporinetreated rats (35.9 ± 2.9 versus 116.8 ± 15.0 |xg/g pancreas, in controls P < 0.001). The pancreatic morphology was normal in all cyclosporine-treated Wistar rats, with an absence of the classic signs of autoimmune involvement of the pancreas seen in the spontaneous BB rat diabetes syndrome (e.g., insulitis, periductular inflammation, or pancreatic lymphocytic infiltration). When cyclosporine was stopped, 60-min glucose values *Glucose significantly different (P < 0.05) in CsA-treated versus controls, flnsulin significantly different (P < 0.05) in CsA-treated versus controls. Unpaired f-tests were used for statistical analysis.
decreased to near-normal levels at 1 wk, and to control levels by 2 wk (Table 2 and Figure 1 ). Plasma insulin responses remained decreased, but tended to rise at 4 wk. In the 5 Wistar rats that received the higher dose of cyclosporine, resulting in 16-h postdose plasma levels of 1758 ± 70 ng/ml, the glucose intolerance was greater (60-min value, 313 ± 17 mg/dl), whereas the fasting glucose was again unaffected.
In the Sprague-Dawley rats, glucose intolerance also occurred after 1 wk of cyclosporine treatment (60 min glucose, 190 ± 5 versus 173 ± 6 in controls, P < 0.05), despite lower plasma cyclosporine levels than those obtained in either Wistar or BB rats (378 ± 94 ng/ml 16 h postdose, P < 0.05). An increase of the dose to 15 mg/kg/day was followed by a rise in the 16-h postdose plasma cyclosporine levels to 932 ±118 ng/ml, with a sharp rise in the glucose 60 min postchaHenge (242 ± 16 versus 146 ± 7 for controls, P < 0.001). The fasting plasma glucose remained normal.
DISCUSSION
We have demonstrated a glucose intolerance-inducing effect of cyclosporine in male BB rats, Wistar non-BB rats, and Sprague-Dawley rats, using doses of oral cyclosporine that achieve "therapeutic" plasma cyclosporine levels. 16 This suggests that this effect is not strain related. The glucose intolerance occurred after 1 wk, but was absent after 4 h and 2 days. Intolerance seems related to circulating plasma cyclosporine levels, as suggested by the aggravation in both Wistar and Sprague-Dawley rats following an increase in the cyclosporine dose. (The data also suggest strain-related-differences in drug kinetics, since the Sprague-Dawley rats had lower levels at the same dose.) Peripheral hypoinsulinemia was present during several of the tests, and this combined with markedly diminished total pancreatic insulin content after 5 wk of the drug treatment suggest that the major mechanism of glucose intolerance induction is via decreased insulin release, and possibly, decreased insulin biosynthesis. The absence of insulitis and inflammation in the pancreas of glucose-intolerant non-BB rat strains suggests that the immune process seen in diabetes-prone BB rats is not responsible for the B-cell dysfunction. After withdrawal of cyclosporine, the glucose tolerance improved after 2 wk, although plasma insulin responses remained decreased. This suggests that altered insulin sensitivity or insulin resistance may also have been present during cyclosporine administration, and that this effect was reversed more rapidly than was restoration of insulin secretion after withdrawal of the agent. A peripheral component is also suggested by the normal insulin values found in the non-diabetes-prone BB rats. The fasting hypoinsulinemia with euglycemia is harder to reconcile by such a mechanism.
Such effects of cyclosporine on glucose and insulin have been suggested by recent in vivo and in vitro studies. In man, it was reported that when azathioprine-prednisolone was replaced by cyclosporine-prednisolone in four diabetic men with both cadaver kidneys and pancreatic transplants, there was a deterioration in glucose metabolism despite an increase in fasting and stimulated plasma C-peptide.
14 It has been suggested that this effect could be related to a decrease in prednisolone clearance with cyclosporine, 15 but a direct effect of the drug could not be excluded. The usual use of corticosteroids with cyclosporine in human transplantation may explain why glucose intolerance has not been associated more frequently with cyclosporine therapy, in light of the frequency of its occurrence with steroids alone. No study has yet reported on glucoregulation with cyclosporine alone in man.
In cyclosporine-treated male Wistar rats, high doses of cyclosporine (50 mg/kg/day for 7 days) caused hyperglycemia with hypoinsulinemia associated with severe degranulation and hydropic degeneration of islet B-cells. 16 Mouse pancreatic islets in culture showed impaired islet proinsulin biosynthesis and insulin release in the presence of high cyclosporine concentrations. 17 One study, using a short in vitro incubation with the drug, failed to show effects on insulin release. 18 This, taken with the present results, suggests that time of exposure is an important factor in the effect on insulin secretion. At doses in the therapeutic range, we could not identify morphologic changes in the pancreas at the light microscopic level, including the immunoperoxidase stain for insulin. The marked decrease in pancreatic insulin content would be consistent with impaired insulin biosynthesis even at the lower cyclosporine levels.
The mechanisms of this glucose intolerance effect remain to be defined, although our data suggest that: (1) insulin secretion and possibly synthesis is impaired either in absolute terms or in relation to the glucose levels; (2) altered insulin binding and/or action may also play a role; and (3) the glucose intolerance is reversible upon cyclosporine withdrawal. The implications of the present findings are important. In diabetes prevention studies, it could be difficult to differentiate glucose intolerance due to the appearance of the diabetic diathesis, itself, from the cyclosporine effects. In studies of early cyclosporine treatment at diagnosis of diabetes, the glucose intolerance related to cyclosporine therapy may mask beneficial effects of the immunosuppressive therapy at the level of the insulitis. If the glucose intolerance is also found in humans, it may have the same confounding effect in current studies of the early therapy of diabetes with cyclosporine, and in eventual studies aimed at prevention in susceptible individuals. It is noteworthy that 100 ng/ml of cyclosporine in the medium of human islet cultures in vitro is sufficient to cause decreased insulin response to glucose.
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